Biohaven Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.05.18	Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) (PR Newswire)
04.05.18	This Day That Year: Biohaven Pharma (RTTNews)
03.05.18	CONSOL Energy Announces Results for the First Quarter 2018 (PR Newswire)
23.04.18	BHVN In Focus, Fresenius Calls Off Deal To Buy AKRX, Good News For GUD (RTTNews)
23.04.18	Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain... (PR Newswire)
21.04.18	An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…) (RTTNews)
19.04.18	Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles (PR Newswire)
05.04.18	Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference (PR Newswire)
03.04.18	Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer (PR Newswire)
26.03.18	Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine (PR Newswire)
18.03.18	An Ear To The Pharma: 11 Stocks To Watch This Week (RTTNews)
12.03.18	Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading... (PR Newswire)
07.03.18	In The Spotlight: Biohaven Pharma (RTTNews)
07.03.18	FDA Approves New HIV Drug, Mark Your Calendar For BHVN, Watch Out For ZFGN (RTTNews)
06.03.18	Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results (PR Newswire)
06.03.18	Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine (PR Newswire)
01.03.18	Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet (PR Newswire)
21.02.18	Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists (PR Newswire)
18.01.18	Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist (PR Newswire)
09.01.18	Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet (PR Newswire)
21.12.17	Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder (PR Newswire)
27.11.17	Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant (PR Newswire)
20.11.17	Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine (PR Newswire)
16.11.17	Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine (PR Newswire)
15.11.17	Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results (PR Newswire)
06.11.17	Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 (PR Newswire)
01.11.17	Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS) (PR Newswire)
30.10.17	Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute (PR Newswire)
25.10.17	Biohaven Adds Clifford Bechtold as Chief Operating Officer (PR Newswire)
24.10.17	Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder (PR Newswire)
02.10.17	Biohaven Reports Negative Data From Spinocerebellar Ataxia Phase 2/3 Trial (RTTNews)
02.10.17	Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial (PR Newswire)
18.09.17	FDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is MTFB (RTTNews)
15.09.17	Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate... (PR Newswire)
06.09.17	International Isotopes Inc. Announces Dr. Robert Atcher Has Joined The Company Board of Directors (PR Newswire)
14.08.17	Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results (PR Newswire)
07.08.17	Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 (PR Newswire)
04.08.17	Biohaven Appoints Julia P. Gregory to Board of Directors (PR Newswire)
31.07.17	Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine (PR Newswire)
24.07.17	Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine (PR Newswire)
18.07.17	PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology (PR Newswire)
13.07.17	Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs (PR Newswire)
06.07.17	Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome (PR Newswire)
23.06.17	Biohaven Added to Russell Microcap® Index (PR Newswire)
22.06.17	Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives (PR Newswire)
16.06.17	Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results (PR Newswire)
09.06.17	Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer (PR Newswire)
01.06.17	Latest IPO Opportunities Setting Up for a Remarkable 2017 (PR Newswire)
01.06.17	Latest IPO Opportunities Setting Up for a Remarkable 2017 (PR Newswire)
30.05.17	Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Biohaven Pharmaceutical Holding Co Ltd Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten